Nancy A. Melville

News

PV: Novel rusfertide shows ‘impressive’ efficacy

Author:: Nancy A. Melville

Publish date: June 16, 2023

The novel synthetic form of liver hormone hepcidin represents a “paradigm shift” in polycythemia vera treatment, allowing patients to avoid the nee...

News

Multiple sclerosis has a misdiagnosis problem

Author:: Nancy A. Melville

Publish date: June 15, 2023

Experts warn that false-negative diagnoses cause treatment delays, while false-positive diagnoses run the risk for potential harm from needless tre...

News

‘Best’ for most APL patients: Chemo-free regimen

Author:: Nancy A. Melville

Publish date: June 12, 2023

A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and older...

News

Antibiotic prophylaxis may lower SSIs in skin cancer surgery

Author:: Nancy A. Melville

Publish date: June 12, 2023

There’s a lack of evidence from randomized clinical trials of the role of antibiotic prophylaxis in reducing SSI rates among patients undergoing sk...

News

‘Strikingly positive’ effect of novel MS agent

Author:: Nancy A. Melville

Publish date: June 9, 2023

Frexalimab is a novel second-generation monoclonal antibody designed to block the costimulatory CD40/CD40L cellular pathway.

News

`Remarkable’: CAR T therapy for CLL/SLL

Author:: Nancy A. Melville

Publish date: June 8, 2023

Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a manage...

News

PMBCL: Postremission, patients may safely skip radiation

Author:: Nancy A. Melville

Publish date: June 6, 2023

Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found no...

News

Multiple changes in NMOSD treatment for nonmedical reasons tied to poorer outcomes

Author:: Nancy A. Melville

Publish date: June 6, 2023

“Our data highlight that aspects outside of therapeutic efficacy may be remarkably meaningful in the effective suppression of disease advancement.”...

News

Long-term freedom from NMOSD relapse with satralizumab

Author:: Nancy A. Melville

Publish date: June 5, 2023

At week 240 (4.6 years), 72% of satralizumab-treated patients were relapse-free, with 91% free from severe relapse.

News

Groundbreaking new regimen for advanced Hodgkin lymphoma

Author:: Nancy A. Melville

Publish date: June 4, 2023

The immune checkpoint inhibitor nivolumab affords unprecedented improvement in “harmonizing” treatment for adult and pediatric Hodgkin lymphoma pat...

News

Endocrinology pay steadily climbs, gender gap closes

Author:: Nancy A. Melville

Publish date: June 1, 2023

Endocrinologists’ earnings still place them in the lowest five specialties in terms of pay, above infectious diseases, family medicine, pediatrics,...

News

'Paradigm shift’: Luspatercept for MDS

Author:: Nancy A. Melville

Publish date: May 25, 2023

In a first head-to-head comparison study, luspatercept for MDS significantly outperformed epoetin alfa in reducing transfusion dependence.

News

Diabetes, cholesterol meds use drops after bariatric surgery

Author:: Nancy A. Melville

Publish date: May 25, 2023

Undergoing bariatric surgery was associated with a substantial and long-lasting reduction in the use of lipid-lowering and antidiabetic medications...

News

Immunotherapy plus chemo improves quality of life in NSCLC

Author:: Nancy A. Melville

Publish date: May 17, 2023

The delays reported in time to definitive clinically meaningful deterioration “are particularly pertinent, given the anticipated continued improvem...

News

Liquid biopsy assay can predict CRC recurrence early

Author:: Nancy A. Melville

Publish date: May 1, 2023

CRC has a relatively high recurrence rate even after curative-intent therapies.